ARMC5

Across TCGA pan-cancer cohorts, ARMC5 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated ARMC5 data layer compared with 19 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher ARMC5 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated ARMC5 expression acts as an unfavorable survival marker, although some lineages such as CCRCC show a favorable association.

CCRCC, PDAC, and LUAD are the cancer types where ARMC5 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Median	IV	0.785	0.123	.009	16	view →
PDAC	DFS	Median	All	0.711	0.867	.007	14	view →
LUAD	OS	Median	All	0.755	0.936	.001	6	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

ARMC5–CCRCC (OS)

Open the CCRCC breakdown →